Potentially Novel Approach for Treating Advanced Colorectal Cancer with KRAS Mutations.

Published Date: 15 Apr 2024

One-third of patients experience responses when using adagrasib plus cetuximab, with a median overall survival of 15 points 9 months.

Read Full News

Latest News



Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

FDA Bans Red Dye No. 3 From Foods, Ingested Drugs

2.

Improved end-of-life conversations for cancer patients are identified by a new study.

3.

In early dementia, SSRIs enhance cognition and major depression.

4.

More pain, more gain? New biopsy technique found to improve prostate cancer detection

5.

Imfinzi + Imjudo, EU approved for patients with advanced lung cancer and non-small cell lung cancer: AstraZeneca


© Copyright 2025 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot